author-photo

Marie-Anne van Lierde

Novartis

10

Papers

530

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).

2021 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (0)
Novel application of Kaplan-Meier methods to model tolerance for nonadherence to imatinib in patients with chronic myeloid leukemia (CML) in the ADAGIO study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 14349: Sacubitril/Valsartan Reduces All-Cause Mortality and Hospitalizations in HFrEF Patients in a Belgian Real-Life Clinical Setting

2019 Circulation
Show All
- Source
- Cite
- Save
Citations (0)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study

2009 Blood
Show All
- Source
- Cite
- Save
Citations (490)
Patient Nonadherence and Treatment Response to Imatinib in Patients with Chronic Myeloid Leukemia: Results from the ADAGIO Study

2008 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Promoting Patient (pt) Adherence (PA) with Imatinib Treatment (IMRx) in Chronic Myeloid Leukemia (CML): Physicians (MD) Perceptions of Utility (Effectiveness [FX], Feasibility [FB], Cost [CO]) and Rankings of Clinical Applicability (CAPL) of 13 Adherence-Enhancing Strategies (AESs) - Results from the ADAGIO Study.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Canonical Correlation Analysis (CCA) of Imatinib Treatment (ImRx) Nonadherence (NA) with Associated Patient Variables (APVs) in Chronic Myeloid Leukemia (CML) - Results from the ADAGIO Study.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Multimethod Clinical Assessment of Patterns and Prevalence of Nonadherence (NA) to Imatinib Treatment (IMRx) in Patients (Pts) with Chronic Myeloid Leukemia (CML): Results from the ADAGIO Study.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: An open-label Belgian trial

2006 Acta Gastro-enterologica Belgica
Show All
- Source
- Cite
- Save
Citations (3)